Life Science Risk Assessment
Diligence across eight domains, from an automated 24-hour Quick Screen to full reports reviewed by a physician and a biomedical engineer.
The Process
Three steps from intake to report
A short form about the company, its product and its regulatory status. Upload any materials you want read alongside the public record.
Vantage assembles the public record across the domains your report covers. On full reports, a physician and a biomedical engineer review it before release; the Quick Screen is automated.
A report of what the record shows, with each factual claim linked to its source, framed for your role (founder, investor, acquirer, or TTO).
Your Deliverable
What the full reports share. The Quick Screen is different: six signals shown separately, with no composite.
A composite of the eight domain scores, each with its confidence band, read against comparable companies. It summarizes the evidence; it is not a readiness verdict.
All eight domains — regulatory, clinical, IP, reimbursement, commercial, team, financial and competitive — each linked to its sources.
Where the record is strong and where the risks sit, with the evidence behind each, so you can weigh them yourself.
The gaps a reader will ask about first, each anchored to a named record, and the questions only the company can answer.
Our Approach
Not just data: physician and engineer review on every full report.
Every full report is reviewed by Arvind Ravinutala, MD, for the clinical context pure data platforms miss — regulatory nuance, adoption barriers and reimbursement realities.
Aswini Ravinutala, BME, brings device design, manufacturing quality systems and technical feasibility review to every full report.
Reports draw on a proprietary assembly of public records from 34 sources, cited in your report so you can check them.
A founder’s report is framed differently from an investor’s or an acquirer’s, around the decision each one is making.
How It Works
Hypothetical examples of how each report is used. None describes a real engagement.
A fund weighing a Phase 2 program would see the trial-registry record, the late-stage programs in the same class, and the manufacturing questions the public record raises.
How it helps: The clinical and competitive record is in one place before the fund prices the round.
A founder preparing a Series A would see the FDA and CLIA pathway questions, whether existing CPT codes appear to fit, and the registered clinical studies behind the test.
How it helps: The founder sees the reimbursement questions investors will raise before the raise.
An acquirer would see the target’s FDA submissions and recalls, the cybersecurity questions they raise, and the target’s integration claims read against the record.
How it helps: The regulatory and integration questions are on the table before an offer is final.
By Role
Start from the decision you are making.
| You are | Report | Fee |
|---|---|---|
| A founder | Founder Report, or the Complete Package | $7,500 / $15,000 |
| A VC or angel investor | Diligence Report, or a fund license | $20,000 · licenses from $95,000/yr |
| A PE firm | Diligence Report, or Enterprise | $20,000 · Enterprise priced to portfolio |
| Corporate M&A | M&A Report | $25,000 |
| A university TTO | TTO Report, or an annual program | $7,500 · programs $45–75K/yr |
| An incubator or accelerator | Incubator Report, or a cohort license | $7,500 · licenses $45–75K/yr |
| Anyone who needs a fast first read | Quick Screen (automated) | $5,000 |
Pricing
The diligence a physician and biomedical engineer would run on a deal — factual claims cited to their sources, delivered in hours rather than weeks.
Annual License · Flagship
License Vantage as your fund's diligence bench: a set number of Quick Screens and Diligence Reports each year, priced to how many deals you run.
Start with one deal
Fund
Platform
A Fund year bought à la carte — 20 Quick Screens at $5,000 plus 2 Diligence Reports at $20,000 — runs $140,000. The Fund license is $95,000 and includes five seats.
Enterprise — for high-volume funds & PE portfolios: a scoped annual Quick Screen and Diligence Report allowance, priced to your portfolio. See portfolio & PE →
À La Carte
See the exact work on a real deal before you commit — a full, cited read you can check yourself.
Commissioning a single evaluation? Its fee credits in full toward a Vantage License.
Evaluating an acquisition? See the M&A Report ($25,000) →
Founders: Founder Report ($7,500) and Complete Package ($15,000) · Universities and incubators: TTO Report and Incubator Report ($7,500 each), plus annual programs
Factual claims are cited to their sources, and identifiers are checked against the real record before release. Full reports are reviewed through a dual lens: Arvind Ravinutala, MD (practicing physician) on clinical & regulatory, and Aswini Ravinutala, BME (biomedical engineer) on technical, IP & manufacturing.
Example
A sample evaluation of a fictional medical device company
Your Quick Screen is a PDF, delivered within 24 hours of a complete intake. It opens on:
The six signals
Regulatory posture, clinical evidence, IP, reimbursement, team and competitive position, each shown separately with the records it rests on
Sources and coverage
Which records were found for each signal, and where the record is thin
Why Trust Vantage
Covering medical devices, diagnostics, therapeutics and digital health
Clinical perspective from Arvind Ravinutala, MD. Real-world understanding of regulatory workflows, clinical adoption barriers, and investor expectations.
Technical review from Aswini Ravinutala, BME: 10+ years in medical device manufacturing, quality and reliability engineering.
Public records from 34 sources, including FDA, SEC, ClinicalTrials.gov, NIH, CMS and USPTO — cross-referenced and cited in every report.
Questions about how we protect your data?
Data Security & Privacy → • Book a 20-Min Discovery Call →A Quick Screen in 24 hours, or a full report in 48. Book a 20-minute call if you're not sure which fits.
Or email arvind@vantagebiomed.com directly